57
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      Are you tired of sifting through news that doesn't interest you?
      Personalize your Karger newsletter today and get only the news that matters to you!

      Sign up

      • Record: found
      • Abstract: found
      • Article: found

      Macular Hole following Intravitreal Bevacizumab Injection in Choroidal Neovascularization Caused by Age-Related Macular Degeneration

      case-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This report describes formation of a full-thickness macular hole subsequent to an injection of bevacizumab for the treatment of neovascular AMD. This complication may be caused by focal tractional forces on the retinal surface due to either vitreous incarceration at the injection site or contraction of the choroidal neovascularization membrane. Alternatively, it may be due to a toxic effect of bevacizumab on a previously compromised retina.

          Related collections

          Most cited references11

          • Record: found
          • Abstract: not found
          • Article: not found

          Age-related macular degeneration is the leading cause of blindness...

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin).

            To report a series of severe intraocular inflammatory events following intravitreal injections of bevacizumab (Avastin). This procedure is performed on a rapidly increasing number worldwide, and rare complications such as intraocular inflammation, endophthalmitis or intraocular haemorrhage are gaining in importance in clinical routine. This is a single-centre retrospective interventional case series of eight patients with severe intraocular inflammation after intravitreal injection of bevacizumab at one referral centre consecutively seen out of approximately a total of 2500 injections performed in that time period. Patients who developed severe intraocular inflammation after intravitreal injection were evaluated clinically, including slit-lamp examination, best-corrected Snellen visual acuity (VA), slit-lamp photography, optical coherence tomography and fluorescein angiography prior to the event and during follow-up. Patients noticed a painless drop in VA up to 2 days following the injection. All patients had a marked anterior chamber reaction with increased flare and cells, but no hypopyon. Typical posterior segment findings included vitreous cellular infiltrates of pseudogranulomatous aspect. Due to their initial clinical aspect suspicious of an endophthalmitis, three cases were treated with systemic antibiotics, but the final diagnosis was uveitis. Five cases showed a characteristic pseudogranulomatous vitreous infiltration as seen in vitritis and were treated only topically. Characteristic features of an inflammation induced by bevacizumab injection include an early onset with painless loss in VA mostly without conjunctival or ciliary injection. Patients respond to systemic or topical cortisone treatment with slow recovery but without permanent damage. Vitreous haemorrhage and infectious endophthalmitis might be differentiated by time course and symptoms.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Macular hole following intravitreal ranibizumab injection for choroidal neovascular membrane caused by age-related macular degeneration.

                Bookmark

                Author and article information

                Journal
                Case Report Ophthalmol
                COP
                Case Reports in Ophthalmology
                S. Karger AG (Allschwilerstrasse 10, P.O. Box · Postfach · Case postale, CH–4009, Basel, Switzerland · Schweiz · Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.ch )
                1663-2699
                May-Aug 2010
                18 August 2010
                : 1
                : 1
                : 36-41
                Affiliations
                [1] aDepartments of Ophthalmology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
                [2] bSheba Medical Center, Tel Hashomer; both affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
                Author notes
                *Elad Moisseiev, MD, Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Weitzman 6 St., Tel Aviv, 64239 (Israel), Tel. +972 3 697 3408, Fax +972 3 697 3870, E-Mail elad_moi@ 123456netvision.net.il
                Article
                cop0001-0036
                10.1159/000319827
                2969161
                21369348
                4415876a-4b91-4867-8e37-497777efd50f
                Copyright © 2010 by S. Karger AG, Basel
                History
                Page count
                Figures: 2, References: 12, Pages: 6
                Categories
                Published: August 2010

                Ophthalmology & Optometry
                intravitreal injection,age-related macular degeneration,choroidal neovascularization,bevacizumab,macular hole

                Comments

                Comment on this article